Mackenzie Financial Corp Increases Stock Position in Align Technology, Inc. $ALGN

Mackenzie Financial Corp increased its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 29.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 550,797 shares of the medical equipment provider’s stock after buying an additional 124,592 shares during the period. Mackenzie Financial Corp’s holdings in Align Technology were worth $104,282,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALGN. Norges Bank bought a new position in shares of Align Technology in the second quarter worth $155,297,000. Nordea Investment Management AB lifted its holdings in Align Technology by 94.5% during the 2nd quarter. Nordea Investment Management AB now owns 638,341 shares of the medical equipment provider’s stock worth $121,055,000 after purchasing an additional 310,091 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in Align Technology in the 2nd quarter worth about $55,061,000. AQR Capital Management LLC grew its holdings in Align Technology by 104.2% during the 1st quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider’s stock valued at $63,133,000 after buying an additional 206,308 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Align Technology by 32.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after buying an additional 202,616 shares during the period. Institutional investors own 88.43% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on ALGN. Jefferies Financial Group raised their price objective on shares of Align Technology from $140.00 to $155.00 in a research report on Thursday, October 30th. Evercore ISI cut their price target on shares of Align Technology from $220.00 to $170.00 and set an “outperform” rating for the company in a report on Tuesday, November 25th. Zacks Research upgraded shares of Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. Wells Fargo & Company lowered their price objective on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. Finally, Stifel Nicolaus set a $200.00 price objective on Align Technology in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Align Technology has a consensus rating of “Hold” and an average target price of $175.45.

Align Technology Stock Performance

NASDAQ ALGN opened at $147.14 on Friday. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19. The company has a fifty day moving average of $134.45 and a 200-day moving average of $156.42. The company has a market capitalization of $10.56 billion, a P/E ratio of 28.51, a P/E/G ratio of 1.49 and a beta of 1.84.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.23. Align Technology had a return on equity of 14.06% and a net margin of 9.50%.The business had revenue of $995.69 million for the quarter, compared to analysts’ expectations of $980.75 million. During the same quarter in the prior year, the firm earned $2.35 earnings per share. The firm’s revenue was up 1.8% on a year-over-year basis. Align Technology has set its Q4 2025 guidance at EPS. As a group, analysts forecast that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has authorized a share buyback program on Tuesday, August 5th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the medical equipment provider to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.